SCHEMBL150617

SCHEMBL150617

O=Cc1cccc(O)c1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 8/20 0.61
TRIM24 O15164 2/20 0.60
TRIM33 Q9UPN9 2/20 0.60
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
THRB P10828 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31539049 1.00 ERN1 (0.61) ERN1TRIM24TRIM33CA1CA2
SCHEMBL1232196 0.83 LMNA (0.58) ERN1TRIM24TRIM33CA1CA2
SCHEMBL4617412 0.79 ERN1 (0.54) ERN1TRIM24TRIM33MEN1KMT2A
SCHEMBL16954374 0.79 ERN1 (0.41) ERN1TRIM24TRIM33CA1CA2
SCHEMBL503137 0.78 CA1 (0.69) ERN1TRIM24TRIM33CA1CA2
SCHEMBL3703256 0.77 ERN1 (0.40) ERN1TRIM24TRIM33CA1CA2
SCHEMBL40633 0.76 LMNA (0.50) ERN1TRIM24TRIM33CA1CA2
SCHEMBL6048616 0.76 ERN1 (0.67) ERN1TRIM24TRIM33CA1CA2
SCHEMBL29407137 0.76 ERN1 (1.00) ERN1TRIM24TRIM33CA1CA2
SCHEMBL36440 0.76 ERN1 (1.00) ERN1TRIM24TRIM33CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528956-B BODIPY light-cage chemiluminescent molecule, nano microsphere, and synthesis method and application thereof 中南林业科技大学 2025-05-13 CN claimed
CN-119528956-A BODIPY light-cage chemiluminescent molecule, nano microsphere, and synthesis method and application thereof 中南林业科技大学 2025-02-28 CN claimed
CN-118324616-A Synthesis method of 2-bromo-3- (phenylpropyl-2-alkyne-1-yloxy) benzaldehyde and derivatives thereof 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2024-07-12 CN claimed
CN-115572218-B Preparation method of 2-bromo-3-hydroxybenzaldehyde and related chemiluminescent substrate intermediate thereof 江阴勒森生物科技有限公司 2024-04-16 CN claimed
CN-115572218-A Preparation method of 2-bromo-3-hydroxybenzaldehyde and related chemiluminescent substrate intermediate thereof 江阴勒森生物科技有限公司 2023-01-06 CN claimed
CN-109053443-A The bromo- 3- aldehyde radical-phenoxy group of 4-(4-)-benzonitrile synthetic method 杭州华东医药集团浙江华义制药有限公司 2018-12-21 CN claimed
CN-118271158-B Method for synthesizing deuterium-labeled substance containing deuterium atom structural unit 山东大学 2026-05-12 CN disclosed
CN-116829557-B Pentaheterocycle compound, preparation method and application thereof 上海艾力斯医药科技股份有限公司 2026-05-12 CN disclosed
US-12576158-B2 Antibody drug conjugates with cleavable linkers HEIDELBERG PHARMA RESEARCH GMBH (DE) 2026-03-17 US disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 US disclosed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents ASTRAZENECA AB (SE) 2025-09-09 US disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 US disclosed
US-20060047151-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047155-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047149-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047157-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-5750631-A CURABLE EPOXIDIZED PHENOLIC RESIN CONTAINING CHLORINE AND/OR BROMINE; FIREPROOFING, BY-PRODUCT INHIBITION SHELL OIL COMPANY (US) 1998-05-12 US disclosed
US-5077375-A Molding materials SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-12-31 US disclosed
US-5008350-A For encapsulating and laminating electonic components SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410187-B2 Fused tricyclic compounds useful as anticancer agents MCL1, TP53, CCNA2 ERN1 2189/4885TRIM24 3744/4885TRIM33 4054/4885
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R ERN1 1650/4885TRIM24 2673/4885TRIM33 1304/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB ERN1 1926/4885TRIM24 2862/4885TRIM33 2868/4885
US-12576158-B2 Antibody drug conjugates with cleavable linkers PTMS, C3AR1, ANPEP ERN1 3176/4885TRIM24 2670/4885TRIM33 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.